Mucocept-CVN, a genetically enhanced vaginal lactobacillus strain for the prevention of HIV acquisition in women: finalization of formulation for the first-in-human clinical trial
Ended Project Grant Awarded Last action
- Award ID
- R44AI149807
- Recipient
-
Osel, Inc. UEI R5DDHN86ANH9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,391,049
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $1,927,366.00 Federal
- $463,683.00 Non-federal
- Place of performance
- Campbell, CA 95008, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $463,683 | $0 | |
| Amendment | $463,683 | $463,683 | |
| Original award | $1,000,000 | $0 |
Quick answers
Who received award R44AI149807?
R44AI149807 was awarded to Osel, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2020.
How much is award R44AI149807 worth?
$2,391,049 has been obligated on R44AI149807: $1,927,366 in federal funding and $463,683 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award